Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 65.4%

Neg 0% Neu 0% Pos 65.4%

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.